Want to understand the true impact of AI in 3D sample analysis? This episode is straightforward to how machine learning accelerates research and overcomes current limitations.
This episode, 'Machine learning and AI in enhancing image analysis of 3D samples'Exploring how machine learning and AI have become essential tools for 3D image analysis. These powerful technologies transform research workflows, enable faster processing, and provide deeper insight into unprecedented complex biological samples.
Listen to Professor Jens Christian Schwamborn of Luxembourg University and Professor Christophe Deben of Antwerp University. They address current limitations of 3D sample analysis and explain exactly how AI divides these barriers. It significantly reduces processing time and reveals previously hidden information.
In this episode, we explain:
- Why researchers are increasingly adopting machine learning and AI for 3D image analysis
- Limitations of current 3D imaging technology and how to improve AI capabilities
- How increasing availability of large datasets accelerates the shift towards AI-powered image analysis
- A breakthrough that AI could bring to the field of 3D sample analysis
This podcast is provided to you in connection with molecular devices. With innovative life science technology, Molecular Devices enables scientific breakthroughs for academic, pharmaceutical, government and biotechnology customers. For more information, please visit moleculardevices.com.
About the Guest
Professor Jens Christian Schwamborn
In 2002, Jens received his diploma in biochemistry from the University of Witten/Herdecke in Germany and in 2005 a doctorate in biology from the University of Munester in Germany. He worked as a postdoctoral researcher at the Institute of Molecular Biotechnology in Vienna, Austria. Since 2013, Jens is head of the Developmental and Cell Biology Group at the Luxembourg Systems Biomedical Center (LCSB) and is a professor at the University of Luxembourg. In 2019, Jens co-founded Organterapeutics Sarl and is currently CEO. Prior to this, he was co-founder and CSO for Braingineering Technologies Sarl (2016-2018). Over the past few years, his research has focused on neurobiology, stem cell research and Parkinson's disease. In particular, he is interested in using human-induced pluripotent stem cells for the development of brain organoid and assembly models used in in vitro disease modeling.
Professor Christophe Deven
Professor Deben is the head of the Tumor Screening Lab at Antwerp University and focuses on improving 3D in vitro Modeling patient tumors for translational studies, primarily through the use of live cell imaging and OMICS technology. He established a patient-centric ecosystem built on four interconnected pillars. UZA/UantWerp Tumor Organoid Biobank. Orbital oncology, a spin-off that develops automated imaging and data analysis platforms for functional precision medicine and prediction of patient therapy responses. Drugvision.ai, a university-based high-throughput screening facility that supports both academic and industry partners. Sightera Biosciences is a TechBio company that leverages three other pillars to generate high-quality training data for AI-driven drug discovery and development. Through this integrated platform, his work will highly bridge biological models and artificial intelligence to accelerate precision medicine in oncology. Publications and Webinars: www.drugvision.ai/blog.
